arGEN-X creates novel, antibody-based medicines with the potential to make a meaningful impact on patients' lives. In so doing, it will provide significant value to all of its stakeholders.
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics.
Fuelled by the best possible natural immune responses available, our Simple Antibody™ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Capable of generating an unparalleled diversity of potent antibodies against a broad range of diseases, the platform allows for more stringent lead selection criteria, thereby increasing the probability of success down the drug development road.
arGEN-X is a close-knit team of 3 highly complementary antibody experts combining over 30 years of expertise in antibody discovery and development.
Our ambition is clear. Through careful selection of novel, high-potential therapeutic targets, and the discovery and pre-clinical development of antibodies against these targets, we aim to build a strong portfolio of truly innovative antibody therapeutics.
